All patients
Age < 65y (younger) Age > 65y Asian type cancer location (esophagus) cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) PD-L1 < 1% PD-L1 > 1% previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
gastric or gastroesophageal junction cancer (GC), nivolumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ATTRACTION-2 (Kang), 2017 0.63 [0.51; 0.78]
CheckMate 649, 2021 0.80 [0.68; 0.94]
CheckMate 649 (PDL1 CPS>5), 2021 0.71 [0.59; 0.86]
0.72 [0.63 ; 0.82 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021 3 36% 3,029 moderate not evaluable deaths (OS) (extension)detailed results ATTRACTION-2 (Kang), 2017 0.62 [0.51; 0.76]
0.62 [0.51 ; 0.76 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable PFS (extension)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
0.60 [0.48 ; 0.74 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable progression or deaths (PFS)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
CheckMate 649, 2021 0.77 [0.68; 0.87]
CheckMate 649 (PDL1 CPS>5), 2021 0.68 [0.57; 0.82]
0.69 [0.60 ; 0.80 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021 3 53% 3,029 moderate not evaluable DCRdetailed results ATTRACTION-2 (Kang), 2017 1.99 [1.24; 3.18]
1.99 [1.24 ; 3.18 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable objective responses (ORR)detailed results ATTRACTION-2 (Kang), 2017 34.90 [2.12; 573.88]
CheckMate 649, 2021 1.63 [1.30; 2.04]
CheckMate 649 (PDL1 CPS>5), 2021 1.80 [1.35; 2.39]
1.78 [1.26 ; 2.53 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021 3 58% 2,474 moderate not evaluable AE (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.93 [1.10; 3.38]
1.93 [1.10 ; 3.38 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.75; 1.62]
1.10 [0.75 ; 1.62 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.37; 1.12]
0.65 [0.37 ; 1.12 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.93 [0.45; 1.92]
0.93 [0.45 ; 1.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.69 [0.29; 1.66]
0.69 [0.29 ; 1.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.75 [0.52; 1.10]
0.75 [0.52 ; 1.10 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.92 [0.61; 1.40]
0.92 [0.61 ; 1.40 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.13 [0.96; 4.71]
CheckMate 649, 2021 1.98 [1.50; 2.61]
2.00 [1.54 ; 2.59 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable STRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.67 [0.90; 7.91]
CheckMate 649, 2021 1.80 [1.33; 2.44]
1.85 [1.39 ; 2.48 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable TRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.05 [1.36; 3.09]
CheckMate 649, 2021 2.17 [1.49; 3.17]
2.12 [1.60 ; 2.79 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.53 [1.09; 5.83]
CheckMate 649, 2021 1.80 [1.47; 2.21]
1.84 [1.51 ; 2.23 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable TRAE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 1.22 [0.23; 6.37]
CheckMate 649, 2021 7.88 [0.42; 149.34]
2.05 [0.40 ; 10.53 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 15% 2,040 low not evaluable TRAE leading to discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.33; 3.63]
CheckMate 649, 2021 1.85 [1.48; 2.30]
1.81 [1.46 ; 2.26 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
CheckMate 649, 2021 2.12 [1.55; 2.90]
1.49 [0.51 ; 4.32 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 56% 2,040 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.27 [1.34; 3.84]
2.27 [1.34 ; 3.84 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.68 [0.26; 1.81]
0.68 [0.26 ; 1.81 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Colitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
CheckMate 649, 2021 1.06 [0.49; 2.26]
1.13 [0.55 ; 2.32 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
CheckMate 649, 2021 1.45 [0.85; 2.46]
1.46 [0.87 ; 2.46 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 9.86 [0.54; 180.88]
9.86 [0.54 ; 180.88 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.48 [0.07; 3.47]
CheckMate 649, 2021 1.76 [0.96; 3.22]
1.32 [0.46 ; 3.78 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 34% 2,040 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.73 [1.04; 2.86]
1.73 [1.04 ; 2.86 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.81 [0.97; 3.36]
1.81 [0.97 ; 3.36 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
CheckMate 649, 2021 2.38 [0.83; 6.77]
2.33 [0.86 ; 6.29 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
CheckMate 649, 2021 1.18 [0.36; 3.88]
1.15 [0.38 ; 3.55 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.87 [1.61; 5.12]
2.87 [1.61 ; 5.12 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CheckMate 649, 2021 1.03 [0.55; 1.95]
1.01 [0.54 ; 1.90 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.29 [0.96; 1.72]
1.29 [0.96 ; 1.72 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.81 [0.67; 4.92]
1.81 [0.67 ; 4.92 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.40 [0.80; 2.44]
1.40 [0.80 ; 2.44 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.12 [0.54; 2.32]
1.12 [0.54 ; 2.32 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 5.92 [0.71; 49.31]
5.92 [0.71 ; 49.31 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 13.96 [1.83; 106.45]
13.96 [1.83 ; 106.45 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 4.36 [1.79; 10.66]
4.36 [1.79 ; 10.66 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.44 [0.71; 2.95]
1.44 [0.71 ; 2.95 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.69 [0.37; 1.29]
0.69 [0.37 ; 1.29 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Abdominal pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.14 [0.43; 3.04]
1.14 [0.43 ; 3.04 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Anaemia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.97 [0.54; 1.75]
0.97 [0.54 ; 1.75 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Asthenia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.48 [0.54; 11.47]
2.48 [0.54 ; 11.47 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Back pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.73 [0.12; 4.41]
0.73 [0.12 ; 4.41 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Constipation AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.54 [0.20; 1.42]
0.54 [0.20 ; 1.42 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
1.96 [0.22 ; 17.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspepsia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspnoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Fatigue AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.29 [0.07; 1.21]
0.29 [0.07 ; 1.21 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.48 [0.47; 4.67]
1.48 [0.47 ; 4.67 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increased ALT AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.31 [0.34; 5.00]
1.31 [0.34 ; 5.00 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.24 [0.02; 2.68]
0.24 [0.02 ; 2.68 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.47 [0.15; 14.22]
1.47 [0.15 ; 14.22 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Weight decreased AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 10:35 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 5,274,218,273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 855,360,719,721,720,842,642,674,1085,863